Holy Cross Germantown Hospital | |
19801 Observation Drive, Germantown, Maryland 20876 | |
(301) 557-6020 | |
Name | Holy Cross Germantown Hospital |
---|---|
Type | Acute Care Hospital |
Location | 19801 Observation Drive, Germantown, Maryland |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 210065 |
NPI Number | 1245655638 |
Organization Name | HOLY CROSS HEALTH, INC. |
Doing Business As | HOLY CROSS GERMANTOWN HOSPITAL |
Address | 19801 Observation Dr, Germantown, MD 20876 |
Hospital Type | General Acute Care Hospital |
Phone Number | 301-754-7000 |
News Archive
Virginia Commonwealth University researchers have decoded the genome of a bacteria normally present in the healthy human mouth that can cause a deadly heart infection if it enters the bloodstream.
Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
The healthy heart movement in recent years has focused largely on heart disease as the No. 1 killer of women. But the same statistic is true for men, and the reality is grim: The first sign that a man has coronary heart disease could be death, says one University of Alabama at Birmingham expert.
Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of €3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. On a pro forma basis, the combined company would have had 2009 revenues of $16.2 billion. Teva expects to complete the transaction by year-end 2010.
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
› Verified 5 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Virginia Commonwealth University researchers have decoded the genome of a bacteria normally present in the healthy human mouth that can cause a deadly heart infection if it enters the bloodstream.
Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
The healthy heart movement in recent years has focused largely on heart disease as the No. 1 killer of women. But the same statistic is true for men, and the reality is grim: The first sign that a man has coronary heart disease could be death, says one University of Alabama at Birmingham expert.
Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of €3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. On a pro forma basis, the combined company would have had 2009 revenues of $16.2 billion. Teva expects to complete the transaction by year-end 2010.
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
› Verified 5 days ago
Holy Cross Germantown Hospital Acute Care Hospital Location: 19801 Observation Drive, Germantown, Maryland 20876 Phone: (301) 557-6020 |